PTC Therapeutics Quarterly Cash Flow Statement
NASDAQ: PTCTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
PTC Therapeutics free cash flow
In the quarter ended Jun 30, 2026, PTC Therapeutics generated $129.1 million of operating cash flow and spent $2.2 million on capital expenditures. That left free cash flow of $126.9 million, a free-cash-flow margin of 35.2% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
PTC Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 83.50M | -2.81M | -134.97M | 15.90M | -64.85M | 866.56M | -65.89M | -106.65M | -99.18M | -91.58M | -155.79M | -132.97M |
| Net Income growth (YoY) | — | -100.32% | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 15.87M | 15.41M | 12.90M | 11.11M | 7.58M | 7.22M | 6.76M | 6.49M | 7.02M | 55.40M | 80.70M | 62.05M |
| Stock-Based Compensation | 23.29M | 23.42M | 18.52M | 19.43M | 18.54M | 18.06M | 17.24M | 19.75M | 19.24M | 18.38M | 16.51M | 26.94M |
| Change in Working Capital | 9.18M | -109.11M | 89.98M | -87.20M | -16.50M | -36.79M | 32.03M | 13.79M | -10.05M | 54.32M | -83.23M | 9.85M |
| Operating Cash Flow | 129.11M | -59.04M | -34.27M | -66.30M | -58.33M | 870.10M | -30.00M | -76.99M | -71.45M | 70.76M | -100.29M | -14.52M |
| Capital Expenditures | -2.19M | -1.20M | -2.37M | -3.52M | -1.25M | -1.72M | -3.77M | -522.00K | 7.38M | -9.59M | -5.57M | -6.36M |
| Investing Cash Flow | -122.56M | -93.74M | 34.01M | -289.62M | -422.01M | -184.36M | 267.71M | -42.67M | -65.92M | -114.93M | -94.42M | -29.60M |
| Financing Cash Flow | 211.88M | 6.40M | 302.50M | 15.22M | 3.96M | 9.41M | 26.47M | -17.63M | 246.48M | 540.00K | 620.49M | 3.36M |
| Net Change in Cash | 215.90M | -147.90M | 312.03M | -346.77M | -462.79M | 700.55M | 255.53M | -128.75M | 103.92M | -45.66M | 428.87M | -43.09M |
| Free Cash Flow | 126.92M | -60.24M | -36.65M | -69.82M | -59.58M | 868.38M | -33.77M | -77.51M | -64.08M | 61.17M | -105.85M | -20.88M |
This table shows 12 quarterly periods of PTC Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PTCT's reporting calendar. What is a cash flow statement?